These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 12508485

  • 1. [Successful treatment with fludarabine of chronic lymphocytic leukemia associated with nephrotic syndrome].
    Takei K, Horikoshi A, Hosokawa Y, Sawada S, Horie T.
    Rinsho Ketsueki; 2002 Nov; 43(11):993-7. PubMed ID: 12508485
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Fludarabine-associated autoimmune hemolytic anemia occurring in B-cell chronic lymphocytic leukemia.
    Nishida H, Murase T, Ueno H, Park JW, Yano T, Ikeda Y.
    Leuk Res; 2006 Dec; 30(12):1589-90. PubMed ID: 16542723
    [Abstract] [Full Text] [Related]

  • 5. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
    Perkins JG, Flynn JM, Howard RS, Byrd JC.
    Cancer; 2002 Apr 01; 94(7):2033-9. PubMed ID: 11932906
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Successful treatment for advanced and refractory chronic lymphocytic leukemia with fludarabine phosphate].
    Takeuchi M, Tada A, Soda R, Takahashi K.
    Rinsho Ketsueki; 1997 Sep 01; 38(9):792-4. PubMed ID: 9364873
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [A case of chronic myeloid leukemia occurring during treatment for chronic lymphocytic leukemia].
    Hattori H, Kuwayama M, Kotake T, Karasuno T.
    Gan To Kagaku Ryoho; 2011 Feb 01; 38(2):333-6. PubMed ID: 21368508
    [Abstract] [Full Text] [Related]

  • 14. Fludarabine in chronic lymphocytic leukemia with membranous nephropathy.
    Rocca AR, Giannakakis C, Serriello I, Guido G, Mosillo G, Salviani C.
    Ren Fail; 2013 Feb 01; 35(2):282-5. PubMed ID: 23176062
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
    Tsimberidou AM, Keating MJ, Giles FJ, Wierda WG, Ferrajoli A, Lerner S, Beran M, Andreeff M, Kantarjian HM, O'Brien S.
    Cancer; 2004 Jun 15; 100(12):2583-91. PubMed ID: 15197800
    [Abstract] [Full Text] [Related]

  • 18. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O'Brien S, Sheng S, Esseltine DL, Keating MJ.
    Cancer; 2006 Sep 01; 107(5):916-24. PubMed ID: 16832816
    [Abstract] [Full Text] [Related]

  • 19. Aggressive growth of epithelial carcinomas following treatment with nucleoside analogues.
    Larsen CR, Hansen PB, Clausen NT.
    Am J Hematol; 2002 May 01; 70(1):48-50. PubMed ID: 11994981
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.